Related references
Note: Only part of the references are listed.Interpretation of Brain Volume Increase in Multiple Sclerosis
Tomas Uher et al.
JOURNAL OF NEUROIMAGING (2021)
Neuroimaging Correlates of Cognitive Dysfunction in Adults with Multiple Sclerosis
Maria Petracca et al.
BRAIN SCIENCES (2021)
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study A Randomized Clinical Trial
Ludwig Kappos et al.
JAMA NEUROLOGY (2021)
2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis
Mike P. Wattjes et al.
LANCET NEUROLOGY (2021)
MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice
Jaume Sastre-Garriga et al.
NATURE REVIEWS NEUROLOGY (2020)
Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis
Madeline Bross et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Brain volume loss in individuals over time: Source of variance and limits of detectability
Sridar Narayanan et al.
NEUROIMAGE (2020)
Assessing the effect of an evidence-based patient online educational tool for people with multiple sclerosis called UMIMS-understanding magnetic resonance imaging in multiple sclerosis: study protocol for a double-blind, randomized controlled trial
Insa Schiffmann et al.
TRIALS (2020)
Slowing of brain atrophy with teriflunomide and delayed conversion to clinically definite MS
Robert Zivadinov et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2020)
Pathological cut-offs of global and regional brain volume loss in multiple sclerosis
Tomas Uher et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Pathological cut-offs of global and regional brain volume loss in multiple sclerosis
Tomas Uher et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis
Antonia Valentina Genovese et al.
RADIOLOGY (2019)
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial
Jeffrey A. Cohen et al.
LANCET NEUROLOGY (2019)
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial
Giancarlo Comi et al.
LANCET NEUROLOGY (2019)
Emotions towards magnetic resonance imaging in people with multiple sclerosis
Katharina Engels et al.
ACTA NEUROLOGICA SCANDINAVICA (2019)
Comparing longitudinal brain atrophy measurement techniques in a real-world multiple sclerosis clinical practice cohort: towards clinical integration?
H. N. Beadnall et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2019)
Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets
Nicola De Stefano et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets
Nicola De Stefano et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Thalamic atrophy in multiple sclerosis: A magnetic resonance imaging marker of neurodegeneration throughout disease
Christina J. Azevedo et al.
ANNALS OF NEUROLOGY (2018)
Progression of regional grey matter atrophy in multiple sclerosis
Arman Eshaghi et al.
BRAIN (2018)
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Ludwig Kappos et al.
LANCET (2018)
Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI
Houshang Amiri et al.
NEUROIMAGE-CLINICAL (2018)
Establishing pathological cut-offs for lateral ventricular volume expansion rates
Michael G. Dwyer et al.
NEUROIMAGE-CLINICAL (2018)
Brain MRI atrophy quantification in MS From methods to clinical application
Maria A. Rocca et al.
NEUROLOGY (2017)
Brain Atrophy in Multiple Sclerosis Clinical Relevance and Technical Aspects
Jaume Sastre-Garriga et al.
NEUROIMAGING CLINICS OF NORTH AMERICA (2017)
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
S. L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
X. Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis
Michael G. Dwyer et al.
NEUROIMAGE-CLINICAL (2017)
Teriflunomide slows BVL in relapsing MS A reanalysis of the TEMSO MRI data set using SIENA
Ernst-Wilhelm Radue et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2017)
Multi-parametric structural magnetic resonance imaging in relation to cognitive dysfunction in long-standing multiple sclerosis
Marita Daams et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Multi-parametric structural magnetic resonance imaging in relation to cognitive dysfunction in long-standing multiple sclerosis
Marita Daams et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Whole-brain atrophy: ready for implementation into clinical decision-making in multiple sclerosis?
Christina J. Azevedo et al.
CURRENT OPINION IN NEUROLOGY (2016)
Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine
Robert Zivadinov et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2016)
CELL-BASED ASSAYS OF CAG REPEAT INSTABILITY IN THE HUNTINGTIN (HTT) GENE
Tom Massey et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2016)
Automated brain volumetrics in multiple sclerosis: a step closer to clinical application
C. Wang et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2016)
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
Fred Lublin et al.
LANCET (2016)
Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine
Robert Zivadinov et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2016)
Towards a better understanding of pseudoatrophy in the brain of multiple sclerosis patients
Nicola De Stefano et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study
David H. Miller et al.
NEUROLOGY (2015)
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
L. Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Towards a better understanding of pseudoatrophy in the brain of multiple sclerosis patients
Nicola De Stefano et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Spinal cord atrophy in multiple sclerosis and relationship with disability across clinical phenotypes
Evanthia Bernitsas et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2015)
Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study
Douglas L. Arnold et al.
JOURNAL OF NEUROLOGY (2014)
Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes
Nicola De Stefano et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2014)
Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study
Cecilie Jacobsen et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2014)
Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial
Aaron E. Miller et al.
LANCET NEUROLOGY (2014)
Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study
Peter A. Calabresi et al.
LANCET NEUROLOGY (2014)
Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial
Thomas P. Leist et al.
LANCET NEUROLOGY (2014)
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
Peter A. Calabresi et al.
LANCET NEUROLOGY (2014)
Magnetic Resonance Imaging in Multiple Sclerosis - Patients' Experiences, Information Interests and Responses to an Education Programme
Judith Brand et al.
PLOS ONE (2014)
Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis
Omar Khan et al.
ANNALS OF NEUROLOGY (2013)
'The situation and the uncertainty about the coming result scared me but interaction with the radiographers helped me through': a qualitative study on patients' experiences of magnetic resonance imaging examinations
Sofia Carlsson et al.
JOURNAL OF CLINICAL NURSING (2013)
The thalamus and multiple sclerosis Modern views on pathologic, imaging, and clinical aspects
Alireza Minagar et al.
NEUROLOGY (2013)
Human brain changes across the life span: A review of 56 longitudinal magnetic resonance imaging studies
Anna M. Hedman et al.
HUMAN BRAIN MAPPING (2012)
Efficacy and safety of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis: Further outcomes from the IMPROVE study
Nicola De Stefano et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2012)
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
Jeffrey A. Cohen et al.
LANCET (2012)
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
Alasdair J. Coles et al.
LANCET (2012)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor
LANCET NEUROLOGY (2012)
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
Paul O'Connor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor et al.
LANCET NEUROLOGY (2011)
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis
Ernst-Wilhelm Radue et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2010)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Jeffrey A. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial
G. Comi et al.
LANCET (2009)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor et al.
LANCET NEUROLOGY (2009)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
Paul O'Connor et al.
LANCET NEUROLOGY (2009)
Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis
R. Zivadinov et al.
NEUROLOGY (2008)
A widespread distinct pattern of cerebral atrophy in patients with alcohol addiction revealed by voxel-based morphometry
Sergei Mechtcheriakov et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2007)
Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial
M. Rovaris et al.
MULTIPLE SCLEROSIS (2007)
The measurement and clinical relevance of brain atrophy in multiple sclerosis
RA Bermel et al.
LANCET NEUROLOGY (2006)
Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial
M Filippi et al.
LANCET (2004)
Accurate, robust, and automated longitudinal and cross-sectional brain change analysis
SM Smith et al.
NEUROIMAGE (2002)
Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance
David H. Miller et al.
BRAIN (2002)
Whole brain segmentation: Automated labeling of neuroanatomical structures in the human brain
B Fischl et al.
NEURON (2002)
Brain atrophy in relapsing multiple sclerosis:: relationship to relapses, EDSS, and treatment with interferon β-Ia
RA Rudick et al.
MULTIPLE SCLEROSIS (2000)
Share Paper
